Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, discuss where topical PDE4 inhibitors fit in atopic dermatitis and how to measure skin and itch response.
News|Articles|May 1, 2026
7 Dermatology Headlines You Missed in April 2026
Author(s)Tim Smith
Fact checked by: Ryan Livingston
This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.
Advertisement
Advertisement
During the month of April 2026, HCPLive highlighted a diverse series of developments across the
Related to this article
Shannon C. Trotter, DO, and Mona Shahriari, MD, discuss burnout, people-pleasing, public speaking, and the real life behind physicians’ polished personas.
ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B psoriasis trial.
This segment of Nguyen's 2026 Fall Clinical Dermatology interview highlights key insights on early dermatology career strategies and other information.
Alia Galadari, MD, discusses subtle erythema, commonly missed diagnoses, and research gaps to help clinicians recalibrate their approach to skin of color.
Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
In the SCENARIO trial, a 15-week weight-loss program cut recurrent vascular events by 67% in patients with obesity after minor ischemic stroke or TIA.
Advertisement
Advertisement